Drug-coated balloon	Percutaneous transluminal angioplasty	Clinically-driven target lesion revascularization rate	1628	1693	The 12-month CD-TLR rate was 3% for DCB vs 19% for PTA (p=0.012).
Drug-coated balloon	Percutaneous transluminal angioplasty	Procedure success	-1	-1	<td colspan="1" rowspan="1">Procedure success</td><td colspan="1" rowspan="1">66/68 (97)</td><td colspan="1" rowspan="1">32/32 (100)</td><td colspan="1" rowspan="1">&gt;0.999</td>
Drug-coated balloon	Percutaneous transluminal angioplasty	12-month primary patency	1497	1629	Patients treated with DCBs exhibited superior 12-month primary patency (89%) compared to patients treated with PTA (48%, p<0.001). T
Drug-coated balloon	Percutaneous transluminal angioplasty	Procedure success	15840	15887	Procedure success 66/68 (97) 32/32 (100) >0.999
Drug-coated balloon	Percutaneous transluminal angioplasty	Walking distance improvement 	20661	20779	At 12 months, both groups showed similar improvement in walking distance (23.7±37.8 m DCB vs 8.8±29.8 m PTA; p=0.156).
Drug-coated balloon	Percutaneous transluminal angioplasty	Clinically-driven target lesion revascularization rate	1628	1692	The 12-month CD-TLR rate was 3% for DCB vs 19% for PTA (p=0.012)
Drug-coated balloon	Percutaneous transluminal angioplasty	Device success	15796	15839	Device success 97/97 (100) 33/34 (97) 0.260
Drug-coated balloon	Percutaneous transluminal angioplasty	12-month primary patency	1497	1627	Patients treated with DCBs exhibited superior 12-month primary patency (89%) compared to patients treated with PTA (48%, p<0.001).
